Enveric Biosciences Inc (ENVB) - Total Liabilities
Based on the latest financial reports, Enveric Biosciences Inc (ENVB) has total liabilities worth $905.88K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Enveric Biosciences Inc (ENVB) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Enveric Biosciences Inc - Total Liabilities Trend (1994–2024)
This chart illustrates how Enveric Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Enveric Biosciences Inc assets under control.
Enveric Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Enveric Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Arkle Resources PLC
STU:48O
|
Germany | €615.00K |
|
Omkar Speciality Chemicals Limited
NSE:OMKARCHEM
|
India | Rs2.43 Billion |
|
Global Li-Ion Graphite Corp
F:0TD
|
Germany | €932.32K |
|
Octopus Aim VCT 2 PLC
LSE:OSEC
|
UK | GBX367.00K |
|
James Cropper PLC
LSE:CRPR
|
UK | GBX52.55 Million |
|
Lion Group Holding Ltd
NASDAQ:LGHL
|
USA | $42.46 Million |
|
Satis Group S.A.
WAR:STS
|
Poland | zł274.74 Million |
Liability Composition Analysis (1994–2024)
This chart breaks down Enveric Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Enveric Biosciences Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enveric Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enveric Biosciences Inc (1994–2024)
The table below shows the annual total liabilities of Enveric Biosciences Inc from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.49 Million | -36.43% |
| 2023-12-31 | $2.34 Million | -41.35% |
| 2022-12-31 | $4.00 Million | -9.45% |
| 2021-12-31 | $4.41 Million | +547.81% |
| 2020-12-31 | $681.25K | -95.26% |
| 2019-12-31 | $14.38 Million | -23.81% |
| 2018-12-31 | $18.88 Million | -42.35% |
| 2017-12-31 | $32.75 Million | +17.61% |
| 2016-12-31 | $27.84 Million | +105.09% |
| 2015-12-31 | $13.58 Million | +151490.01% |
| 2014-12-31 | $8.96K | -63.73% |
| 2013-12-31 | $24.70K | -3.78% |
| 2012-12-31 | $25.67K | +43.43% |
| 2011-12-31 | $17.89K | -64.66% |
| 2010-12-31 | $50.64K | +326.75% |
| 2009-12-31 | $11.87K | -44.04% |
| 2008-12-31 | $21.21K | -55.73% |
| 2007-12-31 | $47.90K | -44.99% |
| 2006-12-31 | $87.08K | -51.50% |
| 2005-12-31 | $179.52K | -73.06% |
| 2004-12-31 | $666.31K | +166.77% |
| 2003-12-31 | $249.77K | -21.21% |
| 2002-12-31 | $317.01K | -7.18% |
| 2001-12-31 | $341.54K | -57.64% |
| 2000-12-31 | $806.35K | -40.26% |
| 1999-12-31 | $1.35 Million | -44.83% |
| 1998-12-31 | $2.45 Million | +49.20% |
| 1997-12-31 | $1.64 Million | +87.79% |
| 1996-12-31 | $873.32K | +24.76% |
| 1995-12-31 | $700.00K | -22.22% |
| 1994-12-31 | $900.00K | -- |
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage fo… Read more